The EMI Steering Committee manages the strategic direction of the programme and makes decisions in relation to its operational aspects. The Committee meets annually to:
- Review Expressions of Interest (EoIs) for research projects
- Review recruitment and progress for EMI trainees and clinical lecturers
- Review, propose and manage training events and opportunities (via the Training Sub-committee, listed below).
Steering Committee
Prof Ian Wilkinson (Chair) - Head of the Division of Experimental Medicine and Immunotherapeutics - EMI Programme Director
Dr Ben Challis - AstraZeneca industry partner - Co-director of the EMI Programme
Dr Nicolas Wisniacki - GlaxoSmithKline industry partner - Co-director of the EMI Programme
Dr Luis Pennanen (Secretary) - EMI Programme Manager
Prof David Jayne - Division of Experimental Medicine and Immunotherapeutics
Prof Duncan Jodrell - Department of Oncology
Prof Sadaf Farooqi – Institute of Metabolic Science Metabolic Research Laboratories
Dr Carmel McEniery – Division of Experimental Medicine and Immunotherapeutics
Dr Ferdia Gallagher – Department of Radiology
Dr Joseph Cheriyan - Division of Experimental Medicine and Immunotherapeutics
Dr Mark Evans – Institute of Metabolic Science Metabolic Research Laboratories
Prof Menna Clatworthy – NIHR Cambridge Biomedical Research Centre
Dr Mike Allison – Cambridge University Hospitals
Ms Kerry-Louise Print – Postgraduate Education and Clinical Academic Training
Training Sub-committee
Dr Joseph Cheriyan (Chair) - Division of Experimental Medicine and Immunotherapeutics
Prof Ian Wilkinson - Head of Division of Experimental Medicine and Immunotherapeutics
Dr Ben Challis - AstraZeneca industry partner
Dr Phil Ambery - AstraZeneca, Global Clinical Leader in Diabetes
Ms Kerry-Louise Print - Postgraduate Education and Clinical Academic Training